Status:
COMPLETED
Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)
Lead Sponsor:
Novartis
Conditions:
Knee Osteoarthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study will evaluate the efficacy and safety of using lumiracoxib in the treatment of patients with knee osteoarthritis (OA)
Eligibility Criteria
Inclusion
- Primary osteoarthritis of knee (confirmed by American College of Rheumatology \[ACR\] criteria).
- Requirement of regular non-steroidal anti-inflammatory drug (NSAID) therapy.
Exclusion
- Evidence of active peptic ulceration within 12 months prior to the screening visit or history of active gastrointestinal bleeding within the previous 5 years.
- Known hypersensitivity to analgesics, antipyretics, or NSAIDS (including celecoxib).
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
1684 Patients enrolled
Trial Details
Trial ID
NCT00367315
Start Date
September 1 2003
Last Update
May 21 2012
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis
Nuremberg, Germany
2
Novartis
Basel, Switzerland